Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lorina Dudkin"'
Autor:
Jonathan A. Pachter, Peter J. Houghton, Lee D. Arnold, Robert Wild, Neil W. Gibson, David M. Epstein, Lorina Dudkin, Mark Bittner, Jennifer Workman, Jennifer Kahler, Christine Mantis, Yan Yao, Andy Cooke, Andrew P. Crew, Prafulla C. Gokhale, Shripad V. Bhagwat
Supplementary Figures 1-9 and Tables 1-3 from Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9ab41947de32aae0fe5fca829aab12
https://doi.org/10.1158/1535-7163.22496358.v1
https://doi.org/10.1158/1535-7163.22496358.v1
Autor:
Jonathan A. Pachter, Peter J. Houghton, Lee D. Arnold, Robert Wild, Neil W. Gibson, David M. Epstein, Lorina Dudkin, Mark Bittner, Jennifer Workman, Jennifer Kahler, Christine Mantis, Yan Yao, Andy Cooke, Andrew P. Crew, Prafulla C. Gokhale, Shripad V. Bhagwat
Supplementary Methods and Figure Legends 1-9 from Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a574faa50b2771bf5de2007cc92ce22
https://doi.org/10.1158/1535-7163.22496355.v1
https://doi.org/10.1158/1535-7163.22496355.v1
Autor:
Jonathan A. Pachter, Peter J. Houghton, Lee D. Arnold, Robert Wild, Neil W. Gibson, David M. Epstein, Lorina Dudkin, Mark Bittner, Jennifer Workman, Jennifer Kahler, Christine Mantis, Yan Yao, Andy Cooke, Andrew P. Crew, Prafulla C. Gokhale, Shripad V. Bhagwat
The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR is a clinically validated target. mTOR forms two distinct multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, metabolism, prol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4546d5b478a915123119734a9363799a
https://doi.org/10.1158/1535-7163.c.6535242
https://doi.org/10.1158/1535-7163.c.6535242
Autor:
Peter J. Houghton, Christopher L. Morton, Larisa V. Debelenko, Catherine Billups, Lorina Dudkin, Raushan T. Kurmasheva
Signaling through the type 1 insulin-like growth factor receptor (IGF-1R) occurs in many human cancers, including childhood sarcomas. As a consequence, targeting the IGF-1R has become a focus for cancer drug development. We examined the antitumor act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc42c6fcb2b905e5250d7fac76f03a2e
https://doi.org/10.1158/0008-5472.c.6500084.v1
https://doi.org/10.1158/0008-5472.c.6500084.v1
Autor:
Peter J. Houghton, Christopher L. Morton, Larisa V. Debelenko, Catherine Billups, Lorina Dudkin, Raushan T. Kurmasheva
Supplementary Materials and Methods, Tables 1-3, Figures 1-2 from The Insulin-like Growth Factor-1 Receptor–Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ef9f293b3842462b46953c48dddd8db
https://doi.org/10.1158/0008-5472.22382060
https://doi.org/10.1158/0008-5472.22382060
Autor:
Peter J. Houghton, Raushan T. Kurmasheva, Catherine A. Billups, Larisa V. Debelenko, Lorina Dudkin, Christopher L. Morton
Publikováno v:
Cancer Research. 69:7662-7671
Signaling through the type 1 insulin-like growth factor receptor (IGF-1R) occurs in many human cancers, including childhood sarcomas. As a consequence, targeting the IGF-1R has become a focus for cancer drug development. We examined the antitumor act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de96eb894ba0268db634208869781364
https://doi.org/10.1158/0008-5472.can-09-1693
https://doi.org/10.1158/0008-5472.can-09-1693
Autor:
Maryam Fouladi, Clinton F. Stewart, Burgess B. Freeman, Peter C. Adamson, Lorina Dudkin, John Tim Wright, Thomas K. Chin, Peter J. Houghton, Mark Krailo, Wayne L. Furman, Roseanne Speights, Susan M. Blaney, Ashish M. Ingle
Publikováno v:
Journal of Clinical Oncology. 24:3678-3685
Purpose To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the histone deacetylase inhibitor, depsipeptide, in children with refractory or recurrent solid tumors. Patients a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d28baf0ce87fab2ec2b0e1bceefa1f54
https://doi.org/10.1200/jco.2006.06.4964
https://doi.org/10.1200/jco.2006.06.4964
Autor:
Shripad V. Bhagwat, Lee D. Arnold, Prafulla C. Gokhale, Andrew P. Crew, Lorina Dudkin, Yan Yao, Jennifer Kahler, Andy Cooke, Jennifer E. Workman, Robert A. Wild, Peter J. Houghton, David Epstein, Christine Mantis, Neil W. Gibson, Jonathan A. Pachter, Mark Bittner
Publikováno v:
Molecular cancer therapeutics. 10(8)
The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR is a clinically validated target. mTOR forms two distinct multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, metabolism, prol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0c2c2ff0e83a89e6c26782f29461e45
https://pubmed.ncbi.nlm.nih.gov/21673091
https://pubmed.ncbi.nlm.nih.gov/21673091
Autor:
Peter J. Houghton, Xiongwen Zhang, Michael B. Dilling, Glen S. Germain, Franklin C. Harwood, Lorina Dudkin, Arun L. Jayaraman
Publikováno v:
The Journal of biological chemistry. 277(16)
To determine whether inhibition of either the ribosomal p70 S6 kinase or eukaryotic initiation factor (eIF) 4E pathways downstream of the mammalian target of rapamycin, mTOR, contributes to rapamycin-induced growth arrest, clones of Rh30 rhabdomyosar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5c95348ab4df5deb69f74e6f61afb1a
https://pubmed.ncbi.nlm.nih.gov/11847216
https://pubmed.ncbi.nlm.nih.gov/11847216